The Bioryx Platform has allowed the science of nanotechnology to enter into global manufacturing that will revolutionize the limits of commercial products. Arryx’s Bioryx Platform is a major advance in the rapidly expanding field of nanotechnology. The platform allows for the manufacture and processing of unlimited numbers of micro or nanoscopic components. This enables nanotubes to be manipulated for widespread commercial use, and to move from the area of scientific curiosity to a major industrial tool. The platform has made possible entirely new categories of products in every area from cosmetics to nanoelectronics. In 2006 Arryx was acquired by Maemonetics, the leader in blood management.